Alnylam Reports Strong Q4 Earnings

Got story updates? Submit your updates here. ›

Alnylam Pharmaceuticals, a leading RNA interference drug developer, reported fourth-quarter net income of $111.5 million, a significant turnaround from a loss in the same period a year earlier. The company's earnings per share of $1.25 exceeded analyst estimates, though its revenue of $1.1 billion fell short of expectations.

Why it matters

Alnylam's strong financial performance in Q4 reflects the growing commercial success of its innovative RNA-based therapies, which have the potential to treat a wide range of genetic and rare diseases. The company's ability to exceed earnings forecasts despite a revenue miss suggests it is effectively managing costs and optimizing the profitability of its product portfolio.

The details

Alnylam reported Q4 net income of $111.5 million, or $0.82 per share, compared to a loss in the same quarter of 2025. Adjusted for one-time items, the company's earnings per share were $1.25, topping the average analyst estimate of $1.16. However, Alnylam's Q4 revenue of $1.1 billion fell short of the $1.14 billion expected by Wall Street. For the full year 2026, Alnylam reported net income of $313.7 million, or $2.33 per share, marking a return to profitability after a loss in the prior year. Annual revenue came in at $3.71 billion.

• Alnylam reported its Q4 2026 and full-year 2026 financial results on February 12, 2026.
• In the same quarter a year earlier, Alnylam reported a net loss.